HHS Seeks New Advisers to Revive Dormant CDC Vaccine Panel
The U.S. Department of Health and Human Services (HHS) is beginning to recruit new vaccine advisers to revive a Centers for Disease Control and Prevention (CDC) vaccine advisory panel that has been dormant for the past year.
Sioux Falls, SD, October 29, 2026 — The U.S. Department of Health and Human Services (HHS) has initiated a recruitment process for new vaccine advisers. The objective is to re-establish a critical advisory panel within the Centers for Disease Control and Prevention (CDC) that has been inactive for approximately the last 12 months.
The dormant panel played a significant role in providing expert guidance on vaccine policy and recommendations. The revival of this advisory group by HHS signals a renewed focus on leveraging external expertise to inform CDC’s public health strategies related to immunizations. Specific details regarding the exact timeline for the recruitment or the planned operational start date for the revived panel were not immediately available.
The Centers for Disease Control and Prevention, a principal agency of the HHS, relies on such advisory committees to review scientific data and provide recommendations on a wide range of public health issues, including vaccine safety and efficacy. The past year of dormancy for this specific vaccine advisory panel means that a significant period has passed without this particular source of expert input being formally active.
The recruitment effort aims to bring in a new cohort of advisers who can contribute to the panel’s future work. The specific criteria for selecting new advisers and the full scope of the panel’s responsibilities once revived are expected to be detailed as the process moves forward. The names of the individuals leading the recruitment within HHS were not provided in the summary.
Vaccine advisory panels are crucial for navigating complex public health challenges, especially in areas like infectious disease outbreaks and the development of new immunization strategies. The reactivation of this CDC panel by HHS is anticipated to bolster the agency’s capacity to address evolving public health needs concerning vaccines. Further information on the composition of the new panel and its initial agenda is awaited.
Story summarized from the original created by Joseph Choi,Nathaniel Weixel on thehill.com, see more information here.
Media gallery
